This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
In December 2017, the 14th “Conversations in Oncology” meeting was held in Shanghai, China. This meeting aimed to discuss the latest scientific and clinical data in the treatment of NSCLC in the era of biomarkers and targeted therapeutics, focusing on the impact this data may have on current patient treatment practices.
To view highlights from the discussion and slides from the various presentations, simply click on the item of your choice below.
Webcast of the roundtable discussion on sequencing TKIs for maximal clinical benefit: factors for consideration
Year in Review: Therapeutic Advances in Treating Advanced NSCLC
Plenary session led by Barbara Melosky
State of the Art in Molecular Testing and Current Diagnostic Challenges
Plenary session led by Mike Zhu
EGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI
Plenary session led by Daniel Tan
TKI Choice in EGFR-M+ NSCLC
Case Study–Based Roundtable Discussion moderated by Keunchil Park with expert panel David Heigener and Jong-Mu Sun
Sequencing TKIs for Maximal Clinical Benefit: Factors for Consideration
Plenary session led by Keunchil Park
Real-World Efficacy of EGFR TKIs
Led by Jong-Mu Sun
Treatment Options for Special NSCLC Patient Populations: Brain Mets, Elderly Patients, Uncommon Mutations
Plenary session led by David Heigener, Darren Lim, and Barbara Melosky
Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung
Led by Shun Lu
Treatment Selection in Squamous Cell Carcinoma
Case-Based Roundtable Discussion moderated by Shun Lu with expert panel Yongfeng Yu, Darren Lim, and Barbara Melosky
Overview of Boehringer Ingelheim in Oncology
Led by Victoria Zazulina
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue